Skip to content
Sign in
SWC 2026 FinalistGrand Final: Main Stage

Legit.Health

CE-marked, ISO 13485 dermatology AI that supports diagnosis and scores severity from photos, partnering with NHS and Spanish health services.

Bilbao, Spain, EuropeHealthTech, AI in dermatology (medical device)Bilbao Regional 2026 (winner; 26 June 2026, B Accelerator Tower / B Acceleration Week)
Stage
SeedAI at the core
Product
On the marketStrong traction
Funding raised
$5.7Mdisclosed
Founded
20197 years ago
Founders
4Andy, Taig…
Global score
6.3Grade BRank 6 of 151

Overview

Legit.Health is an AI-based medical device that helps dermatologists and doctors diagnose, assess the severity of and monitor skin diseases from photos.

Traction

Strong traction

CE-marked medical device (ISO 13485), with partners listed such as NHS, SERMAS, SESPA, Sanitas, Adeslas, Novartis and Almirall.

Market

AI in dermatology

Dermatology faces long waiting lists and specialist shortages, while skin conditions are among the most frequent reasons for primary care visits. Photo-based AI triage and objective severity scoring help health systems prioritise referrals and help pharma measure treatment response in trials. Buyers are public health services, private insurers and pharma companies; reimbursement models are still forming. CE marking and ISO 13485 create a meaningful regulatory barrier.

Addressable market

2025
$1.4B
2030
$4.2B
+24% a year

AI in dermatology: $1.42bn in 2025, +24%/year (Next Move Strategy Consulting); Mordor uses a broader $8.3bn scope.

Customers

Public health services (NHS, SERMAS, SESPA), private insurers (Sanitas, Adeslas), pharma (Novartis, Almirall), dermatologists and primary care doctors.

Who signs the cheque

Health-system digital/innovation directors, insurer medical directors, pharma medical affairs and clinical operations.

Geographies

  • Spain
  • United Kingdom
  • European Union

Drivers

  • Dermatologist shortages and teledermatology growth
  • Need for objective severity scores in clinical trials
  • Insurer cost-containment through triage

Headwinds

  • Reimbursement model to be proven
  • Competition in dermatology AI
  • FDA approval needed for the US

The AI in dermatology market is valued at $1.42bn in 2025 (+24%/year, $11.9bn in 2035) according to Next Move Strategy Consulting; Mordor uses a broad scope of $8.3bn.

Scalability 7/10. CE-marked medical device software, deployable across the EU; constraint: FDA approvals and integration with health systems.

Market source: nextmsc.com

Technology

Category

Software as a medical device (computer vision)

AI at the coreComputer visionMachine learning / predictive

Maturity

  1. R&D
  2. Prototype
  3. Pilot
  4. On the market
  5. Scaling

in market

How it works

Deep learning on skin images supports diagnosis and calculates automated severity scores, delivered within a CE-marked medical device with a clinical data platform. The quality system is certified ISO 13485.

Moat

Strong in Europe: regulatory clearance, quality system, clinical validation and partnerships with health systems and pharma are expensive to replicate.

Differentiation

Regulated diagnostic support with severity scoring versus consumer skin apps; scalable versus in-person dermatology.

Integration points

  • Telemedicine and primary care platforms
  • EHR systems
  • Clinical trial data systems
  • Insurer member apps

Depends on

  • Medical device regulation (MDR, FDA)
  • Image quality and capture protocols
  • Integration into health-system IT

Use of AI

Deep learning on skin photos to support diagnosis and calculate severity scores for skin diseases.

Product in detail

Computer vision and deep learning on skin images, CE-marked as a medical device, with automated severity scores and a clinical data platform.

Business

Model
B2B licences to health systems and insurers and services to pharma (revenue not published).
Revenue logic
Likely per analysis, per user or per contract; not disclosed.
Go-to-market
Direct partnerships with public and private health providers and pharma; strategic investors Mutua Madrileña and Telefónica's Wayra.

Next milestones

  1. FDA clearance
  2. Reimbursed national-scale rollout
  3. Next funding round to scale internationally

Key risks

  • Reimbursement uncertainty
  • Competition
  • Long public procurement

Opportunities

3 found in the network

Concrete moves for Legit.Health inside the network: who to sell to, sell through, build with or raise from, each with the reasoning, the evidence and the first step.

  • Distribution 1
  • Co-development 1
  • Investors 1

Distribution1

A channel or customer base to reach together

Power photo dermatology in an African and Indian Ocean primary-care OS

TIBOK runs an AI-native primary-care operating system in Mauritius, already offers dermatology by photo and distributes white-label to partners such as C-Care Madagascar. As an AI-model-agnostic platform it could embed a CE-marked dermatology engine, giving Legit.Health a distribution channel into markets where dermatologists are scarce and giving TIBOK regulated decision support.

35%confidence

Evidence from the records

  • “CE-marked medical device (ISO 13485)”
  • “dermatology by photo”
  • “First white-label distributor contract signed with C-Care Madagascar (19 November 2026)”
If it works
A per-consultation integration that opens Indian Ocean and African markets for Legit.Health.
First step
Schedule a technical call to review Legit.Health's API and pricing per analysis against TIBOK's photo-dermatology workflow.

Co-development1

An integration or joint product

Extend severity scoring to scalp and hair-loss conditions

HairCoSys analyses hair and scalp images to detect hair loss early and is rolling out across salon networks in Hong Kong. Legit.Health's regulated severity-scoring expertise could help HairCoSys move from cosmetic to medical-grade claims, while HairCoSys's salon channel gives Legit.Health an Asian consumer-facing route for alopecia triage.

20%confidence

Evidence from the records

  • “automated severity scores”
  • “AI image analysis via iPad and a handheld lens”
  • “rollout announced across the Powell Group's 70 salons”
If it works
A co-developed scalp module and an Asian channel test.
First step
Hold a call between both AI leads to compare datasets and regulatory scope.

Investors1

A fund whose thesis fits

Pharma-oriented HealthTech investor

Legit.Health's pharma partnerships (Novartis, Almirall) suggest a revenue line in trials and real-world evidence. PharmStars invests in HealthTech at pre-seed and seed globally with a pharma angle and led Cromodata's pre-seed in the network.

25%confidence

Evidence from the records

  • “partners listed such as NHS, SERMAS, SESPA, Sanitas, Adeslas, Novartis and Almirall”
  • “PharmStars Ventures (lead), Sancus Capital, Gabriela Pittis (business angel)”
If it works
Pharma introductions and a potential co-investor in the next round.
First step
Ask Cromodata's founders for an introduction to PharmStars.

Analyst reading of 21 Nov 2026, from the public record of the network. Method: analyst-ai.

Investors that fit

ENISA: Spain's public lender to innovative startups and SMEs, providing participative loans of €25,000-1.5M with no personal guarantees.

Spanish CE-marked AI dermatology with NHS, Sanitas and Novartis partners: Spanish-domiciled innovator suited to a participative loan alongside equity.

55%confidence

Evidence from the records

  • “AI in dermatology (medical device)”
  • “Spain”
First step
Apply for an ENISA growth loan to extend runway non-dilutively.

Boston fund investing only in PharmStars accelerator graduates: pharma-ready digital health, first 12 deals in rare-disease digital health.

CE-marked dermatology AI already partnering with Novartis and Almirall: textbook 'pharma-ready digital health'. It may be later-stage than typical cohorts (seed, $5.7M raised).

55%confidence

Evidence from the records

  • “partners listed such as NHS, SERMAS, SESPA, Sanitas, Adeslas, Novartis and Almirall”
  • “pharma-ready digital health startups”
Intro path
Cromodata founders (PharmStars graduate).
First step
Ask Legit.Health whether a PharmStars cohort fits its pharma pipeline plans.

Silicon Valley VC ($1.7B AUM, 200+ companies) and Startup World Cup founder, running corporate venture funds for 35+ corporates.

CE-marked dermatology AI with NHS and pharma partners (Novartis, Almirall); a regulated, defensible product that fits a global corporate-health narrative.

50%confidence

Evidence from the records

  • “CE-marked medical device (ISO 13485)”
  • “AI in dermatology (medical device)”
Intro path
Startup World Cup channel; co-investor Wayra.
First step
Share Legit.Health's partner list with the Pegasus health corporate funds.

Sunnyvale innovation platform running industry accelerators worldwide, connecting startups with corporations, governments and universities across ten sectors.

CE-marked dermatology AI used by NHS and insurers (Sanitas, Adeslas): pilot-ready for health corporate members.

45%confidence

Evidence from the records

  • “CE-marked medical device (ISO 13485)”
  • “HealthTech”
Intro path
Co-investor Wayra.
First step
Apply to the health programme with insurer references.

London early-stage investor ($180M Fund VI, 460+ companies, nine unicorns) leading pre-seed and seed rounds across Europe.

Spanish CE-marked dermatology AI used by NHS: health AI, a sector where Seedcamp backed Viz.ai.

40%confidence

Evidence from the records

  • “CE-marked medical device (ISO 13485)”
  • “AI in dermatology (medical device)”
Intro path
Wayra (Legit.Health investor).
First step
Approach Seedcamp for Legit.Health's Series A participation.

Paris VC (~€1B AUM, 100+ startups) backing European-DNA tech with international ambition, pre-seed to Series A.

Spanish CE-marked AI dermatology with NHS and Novartis partners: European health AI at seed.

40%confidence

Evidence from the records

  • “AI in dermatology (medical device)”
  • “CE-marked medical device (ISO 13485)”
First step
Pitch the European expansion story.

Spain-based investor with an empty profile; its only recorded network deal is Argentine clinical-data marketplace Cromodata's pre-seed.

Spanish CE-marked dermatology AI; health-data adjacent, but already seed-funded by Wayra, Mutua Ventures and Grupo Ribera.

25%confidence

Evidence from the records

  • “AI in dermatology (medical device)”
  • “Spain”
First step
Explore participation in Legit.Health's next round.

Investor with no profile in our data; invested an undisclosed amount in Spanish femtech/preventive health startup IKI Health.

Spanish dermatology AI — Spanish health; already well funded.

20%confidence

Evidence from the records

  • “IKI Health”
  • “AI in dermatology (medical device)”
  • “CE-marked medical device (ISO 13485), with partners listed such as NHS, SERMAS, SESPA, Sanitas, Adeslas, Novartis and Almirall.”
Intro path
Founder-to-founder intro via IKI Health (network portfolio company of Max Ventures).
First step
Low priority.

Investment analysis

6.3B

Grade B

Rank 6 of 151

Disruption7.0/10
Business model6.0/10
Market5.0/10
Risk(lower is better)4.0/10

Global score = mean of disruption, model, market and (11 − risk). Last updated 21 Nov 2026.

Regulated AI HealthTech adopted by health systems: priority case.

Disruption

7/10

CE-marked AI medical device in dermatology: a new approach that could change skin diagnosis practice.

Business model

6/10

Listed partners NHS, SERMAS, Sanitas, Novartis, Almirall; revenue not published.

Market

5/10

TAM $1.42bn → base 4; scalability 7/10 (neutral); international: partners in Spain and the United Kingdom (NHS) (+1) → 5/10.

Risk

4/10

Lower is better

Contained risk: regulatory barrier cleared (CE, ISO 13485); competition in dermatology AI and reimbursement to be secured.

Strengths

  • CE marking and ISO 13485
  • Top-tier health and pharma partners

Risks

  • Reimbursement model to be proven
  • Competition in dermatology AI

Funding

$5.7M, disclosed
  1. n.d.

    seedn/a

    Wayra (Telefónica), Grupo Ribera, business angels

  2. oct. 2024 (6 oct. selon Nordic9 ; 24 oct. selon CB Insights)

    seed / capital increaseundisclosed

    Mutua Madrileña (Mutua Ventures, lead), Wayra (Telefónica), Grupo Ribera, business angels

  3. n.d. (rapporté en 2026, sans date)

    cumulative total$7M

    n/a

Amount used in the study. Conservative figure of $5.7M (Caplight); $7M cumulative as upper bound.

Note. Conflicting sources: ~$5.7M (Caplight) vs $7M cumulative (Ecosistema Startup, undated); latest identified round = seed II of Oct. 2024 (Mutua Madrileña lead); no 2026 funding round confirmed

Regional clarified: winner of the Bilbao regional final (26 June 2026). The Mutua/Wayra/Grupo Ribera round is dated October 2024; the $7M is an undated cumulative figure, not a 2026 funding round.

Team

  • Andy Aguilar

    Co-founder & CEO

    Co-founder and CEO of Legit.Health (Bilbao, 2019).

  • Taig Mac Carthy

    Co-founder & COO

    Co-founder, chief operating officer (medical device regulatory affairs).

  • Alfonso Medela

    Co-founder & Chief AI Officer

    Co-founder, head of AI (dermatological computer vision).

  • Gerardo Fernández

    Co-founder & CTO

    Co-founder, chief technology officer.

Sources

Regional final
Bilbao Regional 2026 (winner; 26 June 2026, B Accelerator Tower / B Acceleration Week)
Identification confidence
high
Founding year: 2019 (medium confidence)
Dealroom/CB Insights: 2019 in Bilbao (entity AI Labs Group S.L.); Euronews says 2020; one co-founder profile cites 2017 app.dealroom.co
  1. 1legit.health/
  2. 2ecosistemastartup.com/legit-health-competira-por-us1m-con-su-ia-dermatologica/
  3. 3elreferente.es/?p=169188
  4. 4caplight.com/company/legit-health
  5. 5startupworldcup.io/bilbao-regional
  6. 6nordic9.com/news/legit-health-raised-seed-capital-with-mutua-madrilena-

From the open study Startup World Cup 2026 by TIBOK, based on public sources, verified in November 2026. Scores are an analyst's judgment on an explicit grid, not the jury's.

Wall

Wall

No posts yet